Page last updated: 2024-10-28

hydralazine and Anemia, Hypochromic

hydralazine has been researched along with Anemia, Hypochromic in 1 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Anemia, Hypochromic: Anemia characterized by a decrease in the ratio of the weight of hemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular hemoglobin concentration is less than normal. The individual cells contain less hemoglobin than they could have under optimal conditions. Hypochromic anemia may be caused by iron deficiency from a low iron intake, diminished iron absorption, or excessive iron loss. It can also be caused by infections or other diseases, therapeutic drugs, lead poisoning, and other conditions. (Stedman, 25th ed; from Miale, Laboratory Medicine: Hematology, 6th ed, p393)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Perry, HM1

Other Studies

1 other study available for hydralazine and Anemia, Hypochromic

ArticleYear
Possible mechanisms of the hydralazine-related lupus-like syndrome.
    Arthritis and rheumatism, 1981, Volume: 24, Issue:8

    Topics: Anemia, Hypochromic; Anticholesteremic Agents; Blood Pressure; Diastole; Dose-Response Relationship,

1981